{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:59:41Z","timestamp":1792479581471,"version":"4.5.0"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100017521","name":"Esteve Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CVT\u2010301 (Inbrija) has demonstrated its effectiveness in treating OFF periods in people with Parkinson's disease (PwP). However, its effect on non\u2010motor symptoms (NMS) and quality of life has not been researched yet. Our aim was to analyze the change observed in health\u2010related quality of life (HRQoL) and, as a secondary exploratory analysis, NMS associated with OFF episodes in PwP treated with CVT\u2010301.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>INLEVO\u2010LIFE PD (an open\u2010label study of the effect of INhaled LEVOdopa on quality of LIFE and non\u2010motor symptoms in Parkinson's Disease) is a prospective open\u2010label study conducted in five centers in Spain. The change from baseline (V0) to the end of the observational period (12\u2009\u00b1\u20092\u2009weeks) (V12w) in the 39\u2010item Parkinson's Disease Quality of Life Questionnaire (PDQ\u201039) total score was the primary efficacy measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty PD patients (age 62.3\u2009\u00b1\u20099.2\u2009years; 55% males) were included between March\/2024 and November\/2025. At 12\u2009weeks, 34 patients were using CVT\u2010301 and completed the follow\u2010up (85%). The PDQ39 total score decreased from 43.6\u2009\u00b1\u200924.2 at V0 to 31.4\u2009\u00b1\u200920.6 at V12w (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). A significant decrease was observed in the mean score of 4 domains of the PDQ39. NMS burden was reduced at v12w from the OFF state to 30, 60, and 90\u2009min after using CVT\u2010301 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Mean daily OFF time decreased by 1.6\u2009\u00b1\u20091.9\u2009h (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Adverse events related to CVT\u2010301 were reported in 35% of the patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HRQoL and NMS associated with OFF episodes improved in PwP after 12\u2009weeks using CVT\u2010301.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70731","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:00:04Z","timestamp":1786021204000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improvement in Quality of Life and Non\u2010Motor Symptoms Associated With\n                    <scp>OFF<\/scp>\n                    Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-5111","authenticated-orcid":false,"given":"Diego","family":"Santos Garc\u00eda","sequence":"first","affiliation":[{"name":"Complejo Hospitalario Universitario de A Coru\u00f1a (CHUAC)  A Coru\u00f1a Spain"},{"name":"Grupo de Investigaci\u00f3n en Enfermedad de Parkinson y Otros Trastornos del Movimiento INIBIC (Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a)  A Coru\u00f1a Spain"},{"name":"Hospital San Rafael  A Coru\u00f1a Spain"},{"name":"Fundaci\u00f3n Degen  A Coru\u00f1a Spain"},{"name":"Networking Research Center on Neurodegenerative Diseases (CIBERNED) Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8173-4502","authenticated-orcid":false,"given":"Mar\u00eda","family":"Cerd\u00e1n S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario de Cartagena  Murcia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Y\u00e1\u00f1ez Ba\u00f1a","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Ourense (CHUO)  Ourense Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2436-6499","authenticated-orcid":false,"given":"Iria","family":"Cabo","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Pontevedra (CHOP)  Pontevedra Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ic\u00edar","family":"Cimas Hernando","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Vigo (CHUVI)  Vigo Spain"},{"name":"Hospital de Povisa  Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28726"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13690"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01429-0"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02636-3"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001143"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26611"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30405-8"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.03.026"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.04.004"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.12.012"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1149615"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21844"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000229546.81245.7F"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/26.5.353"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20213"},{"key":"e_1_2_11_18_1","first-page":"153","volume-title":"Recent Developments in Parkinson's Disease","author":"Fanhn S.","year":"1987"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13658"},{"key":"e_1_2_11_20_1","first-page":"152","volume-title":"Third Symposium on Parkinson's Disease","author":"Schwab R. S.","year":"1969"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.11.035"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.07.031"},{"key":"e_1_2_11_23_1","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W.","year":"1976"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2017.05.021"},{"key":"e_1_2_11_25_1","first-page":"28","article-title":"The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice","volume":"4","author":"Busner J.","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12921"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(86)90038-X"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2013.00863"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.24227"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-240026"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107036"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332551"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.10.029"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000540"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70731","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:30:52Z","timestamp":1787725852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/ene.70731"],"URL":"https:\/\/doi.org\/10.1111\/ene.70731","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70731"}}